Momentum Is Building For This Biotech Company
One Biotech Company is starting to see bigger volume by the day while also holding a strong support level around $2….the crazy part is that the leadership behind this team could be responsible for turning this small company into one with potential for a billion dollar pipeline!
ImmunoGen, Inc. (NASDAQ:IMGN) Updates On Pipeline Progress
ImmunoGen, Inc. (NASDAQ:IMGN) a pioneer in the expanding segment of antibody-drug conjugates for the treatment of cancer, issued update on recent highlights and operating performance for the quarter and year closed December 31, 2017. As previously reported, effective January 1, 2017, the company transitioned to a fiscal year closing December 31. The years closed December 31, 2017 and 2016 highlight the twelve-month performance of the respective calendar years. Revenues for the year closed December 31, 2017 came at $115.4 million as against $48.6 million for the year closed December 31, 2016.